Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion: a preliminary report. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004

J Neurosurg Spine. 2004 Jul;1(1):19-23. doi: 10.3171/spi.2004.1.1.0019.

Abstract

Object: The authors compared fusion rates in transforaminal lumbar interbody fusion (TLIFs) when using either autograft or bone morphogenetic protein (BMP) placed in the interbody space.

Methods: Between September 2002 and December 2003, the authors performed 44 TLIF operations. Follow-up data were available for 40 patients. Of the 40 procedures, 19 involved cages filled with iliac crest autograft (Group 1) and 21 involved cages filled with a medium kit of recombinant human (rh) BMP-2 (Group 2). In all Group 2 patients, one BMP sponge was placed anterior to the cage and another was placed within the cage. In 12 of the Group 2 patients, iliac crest autograft was placed posterior to the BMP-filled cage (Group 2A). In the remaining nine Group 2 patients, only local autograft was placed posterior to the BMP-filled cage (Group 2B). Assessment of fusion was performed using dynamic radiography at 3-month intervals. Outcomes were assessed using the Prolo Scale, and iliac crest donor site pain was measured using a Visual Analog Scale (VAS). The mean follow-up period was 9 months (range 3-18 months). In Group 1 patients, one pseudarthrosis was detected. In Group 2 patients, dynamic radiography demonstrated solid fusion in all patients except one in Group 2B. Fifty-eight percent of patients in whom iliac crest autograft was used complained of donor site pain 6 months after surgery (5 of 10 points on the VAS). Symptomatic foraminal bone formation was not observed in any Group 2 patient.

Conclusions: The use of rhBMP-2 is safe in TLIFs when the sponges are placed away from the dura mater, and BMP promotes a more rapid fusion than iliac crest autograft alone. The use of rhBMP-2 in combination with local autograft is an excellent option for promoting solid fusion with TLIF, and it eliminates the possibility of iliac donor site pain.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Bone Morphogenetic Protein 2
  • Bone Morphogenetic Proteins / therapeutic use*
  • Bone Transplantation*
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Ilium / transplantation
  • Intervertebral Disc Displacement / diagnostic imaging
  • Intervertebral Disc Displacement / drug therapy*
  • Intervertebral Disc Displacement / surgery
  • Low Back Pain / diagnostic imaging
  • Low Back Pain / drug therapy
  • Low Back Pain / surgery
  • Lumbar Vertebrae / surgery*
  • Male
  • Middle Aged
  • Pilot Projects
  • Radiography
  • Recombinant Proteins / therapeutic use
  • Spinal Fusion*
  • Spondylolisthesis / diagnostic imaging
  • Spondylolisthesis / drug therapy*
  • Spondylolisthesis / surgery
  • Surgical Sponges
  • Transforming Growth Factor beta*

Substances

  • BMP2 protein, human
  • Bone Morphogenetic Protein 2
  • Bone Morphogenetic Proteins
  • Recombinant Proteins
  • Transforming Growth Factor beta
  • recombinant human bone morphogenetic protein-2